Objectives. Almost all patients with SSc have gastrointestinal manifestations. Small intestinal bacterial overgrowth (SIBO) occurs in 3060% of patients and leads to malnutrition and impaired quality of life. Recent systematic reviews have reported efficacy of treatments for SIBO, but these are not specific to patients with SSc. We conducted a systematic review of the evidence for all possible SIBO treatments in the SSc population.
Introduction
SSc is an autoimmune disease that causes fibrosis of multiple organ systems including the dermatologic, gastrointestinal (GI), pulmonary, renal and musculoskeletal systems. The manifestations of this disease are likely secondary to abnormalities of the innate and adaptive immune systems. In turn, this leads to the production of autoantibodies and cell-mediated autoimmunity, small vessel fibro-proliferative vasculopathy and dysfunction of fibroblasts, which subsequently leads to excessive collagen and accumulation of other matrix components [1] .
GI manifestations have been reported in up to 98% of patients with SSc [24] . Both upper and lower GI tracts can be affected, which may have significant negative effects on quality of life [46] . In SSc, the GI musculature can become progressively fibrosed with types I and II collagen depositing into the muscularis mucosa and lamina propria, leading to reduced contractility [7] . This occurs in concert with fibro-proliferative vasculopathy [1] and GI nerve impairment via autoantibodies against muscarinic (M3) acetylcholine receptors that promote smooth muscle contraction [7, 8] . The resulting delayed gastric emptying and prolonged orocaecal transit time [3] creates an environment conducive to small intestinal bacterial overgrowth (SIBO).
Indeed, SIBO is a common manifestation in SSc with a prevalence of 3062%. It presents with symptoms of abdominal pain or discomfort, bloating, diarrhoea, constipation and abdominal tenderness [7] . Left untreated, SIBO can eventually lead to malnutrition due to malabsorption [9] . In one study of 37 SSc patients, patients affected by SIBO had a longer duration of disease than those who were unaffected with a median of 11 vs 7 years, respectively (P = 0.02). They also experienced significant weight loss within 6 months and scored higher on the University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0, which is a validated scale to assess self-reported GI quality of life [10, 11] . Another validated scale that is not specific to SSc is the Gastrointestinal Quality of Life Index, which can be used to assess symptoms over time [12] . These scales are mostly used for research purposes and screening for SIBO is mainly based on clinical assessment of symptoms.
For diagnosis of SIBO, a North American Consensus Group found that aspiration of small bowel fluid for culture and bacterial count has been considered the gold standard but is flawed by false-positives due to contamination with oral and oesophageal flora and false-negatives due to lack of ability to reach the mid and distal section of the small bowel [13] . Therefore, diagnosis of SIBO is primary made using breath testing as it is non-invasive and relatively inexpensive. This is done by ingesting various carbohydrate substrates such as glucose (sensitivity 2093%, specificity 3086%) or lactulose (sensitivity 3168%, specificity 44100%), which are then broken down by intestinal microbes, producing gases like hydrogen and methane. These gases enter the circulatory system and are expired via the lungs where the change in gases is measured pre-and post-ingestion. The Consensus Group recommended that antibiotics be held 4 weeks prior to initial testing as they can affect hydrogen and methane production, although to an unknown extent [13] . The use of prokinetics can lead to a false-positive due to faster transit time and should be held 1 week prior to testing [13] . Continuing proton pump inhibitors (PPIs) prior to testing is not felt to alter results, but the literature is conflicting [13] .
The most recent EULAR recommendations for the treatment of GI manifestations of SSc are from 2016. These guidelines recommend prokinetics for symptomatic motility issues and rotating antibiotics for malabsorption due to SIBO [14] . Data for the treatment of SIBO in SSc are limited and guidelines have been extrapolated from SIBO in other populations [15, 16] . There have been recent systematic reviews showing efficacy of probiotics and rifaximin in SIBO, but these are not specific to patients with SSc [17, 18] . This systematic review focuses on available evidence for the treatment of SIBO in patients with SSc.
Methods

Systematic review and study selection
The protocol for the review was registered with PROSPERO (identification number CRD42016037395). Articles were included in the systematic review if they: reported primary data from an original study; included adults (518 years old); included a treatment arm for SIBO; reported on SIBO eradication; and were available in English (Fig. 1) . All articles yielded from the search were independently screened for eligibility by two reviewers (N.P., S.M.R.). Using Cohen's k calculation, where random agreement probability was assessed at 0.9, the inter-rater reliability for this process was 1, which represents perfect agreement.
The review was designed to retrieve all evidence on treatment of SIBO in patients with SSc regardless of treatment modality. The literature search was broad in order to find all articles referring to SIBO or bacterial overgrowth in which SSc patients were included.
Data abstraction
The following data were extracted independently in duplicate (N.P. and S.M.R.): author, year, study design, age, gender, disease population, SIBO diagnostic test, type of treatment (including dose and duration), clinical outcomes including SIBO eradication, and adverse events ( Table 1) .
Quality assessment
The Cochrane risk of bias tool was employed to evaluate the studies in this systematic review (Table 2) [22] . Risk of bias was scored by two authors (S.M.R. and K.A.B.) and, where differences existed, a third party (M.L.) was involved as an arbiter. Additionally, the non-randomized studies retrieved in this systematic review were subjected to quality assessment by the Newcastle-Ottawa scale [23] ( Table 3 ). The Newcastle-Ottawa Scale [23] is used to assess the quality of non-randomized studies and includes three aspects of study quality: selection, comparability and exposure. Briefly, there are four criteria to evaluate selection, one criterion to evaluate comparability and three criteria to assess exposure. Each criterion, if achieved, is awarded one star, except for comparability, which can be awarded two stars, for a total of nine. The higher the score, the higher the quality of the study. Two authors (N.P. and S.M.R.) independently assessed articles using the categories of selection, comparability and outcome. Where differences existed, a third party (M.L.) was involved as an arbiter.
Statistical analysis
Pooled data were to be examined via a meta-analysis. However, given the heterogeneity of treatments examined and the relatively small sample sizes, such analyses were not feasible. Instead, data were extracted, summarized in tabular form and assessed qualitatively.
Results
Search results
The literature search identified 5295 publications. Abstracts were reviewed for each publication. Ninetyeight articles relating to the treatment of SIBO were identified, but only five were specific to patients with SSc ( Fig. 1) .
Study characteristics
Five studies were included in this systematic review (Table 1 ). All studies were non-randomized and patients were confirmed to have SIBO based on glucose [7, 10, 19, 21] or lactulose breath tests [20] and, in one study, also with jejunal aspirates [21] . The total number of SSc patients included was 172 with 78 (45.3%) testing positive for SIBO. Eradication rates were 100% in patients treated with octreotide [19] or ciprofloxacin [20] , 73.3% in those receiving rifaximin [21] , 52.4% in those treated with intermittent rotating norfloxacin and metronidazole [7] , and 43% in those treated with 1 month each of amoxicillin, ciprofloxacin and metronidazole [10] .
Study overviews
Of the five studies, one assessed a motility agent for the treatment of SIBO in SSc, whereas the other four un-controlled studies investigated different antibiotic protocols. Given a meta-analysis could not be performed, descriptions and summaries of the evidence are provided.
Soudah et al.
This prospective study included 11 individuals (5 with SSc, 6 controls) [19] . The patients with SIBO ranged from 55 to 65 years of age and their diagnosis of SSc met criteria for diffuse SSc with skin tightness or thickening, sclerodactyly and multisystem involvement. The criteria for diagnosis from 1980 that was used in this study has since been updated and diagnosis is now based on the 2013 ACR/EULAR criteria [24] . They had manometric evidence of esophageal dysmotility and dysphagia, heartburn or both. The SSc patients had been recently treated in hospital for intestinal pseudo-obstruction and all had confirmed SIBO by breath hydrogen testing. Octreotide 50 mg daily was given subcutaneously for 3 weeks. After Tauber et al.
The non-randomized, un-controlled, prospective study by Tauber et al. [10] included 37 SSc patients with intestinal symptoms. Fourteen patients (38%) had a diagnosis of SIBO based on a positive glucose breath test and were treated with rotating antibiotics: amoxicillin 500 mg three times a day for the first month, followed by ciprofloxacin 500 mg twice a day for the second month and metronidazole 500 mg three times a day for the third month. After antibiotics, six patients had a negative breath test (43%), four remained positive and two failed to repeat the test. Two patients died due to intestinal involvement with severe chronic malabsorption, one of whom had also developed Clostridium difficile.
Quality assessment
Overall, the quality of the studies on treatment of SIBO in patients with SSc is low given that there are no randomized controlled trials. According to the Cochrane Risk of Bias [22] , there is generally a high risk of bias given that there is no randomization, allocation concealment or blinding. There were also instances of incomplete and selective reporting of data ( 
Discussion
In total, five non-randomized studies of low quality met the criteria for this systematic review. This included a total of 78 patients with SSc who were also diagnosed with SIBO (Tables 2 and 3 ) [7, 10, 1921] . Given the trial heterogeneity and lack of treatment control arms, a meta-analysis could not be performed. One of the studies investigated the treatment effectiveness of a motility agent, whereas the other four examined different antibiotic regimens. Although Soudah et al. found 100% eradication of SIBO and significant reductions in abdominal pain, nausea, bloating and emesis in patients with diffuse SSc after a 3-week course of octreotide, the study was limited by its small sample size, limiting the generalizability of the results [19] . The study controlled for the potential confounders of alimentation and other known motility agents.
Of note, besides patients with SSc, other patients who have gut dysmotility and SIBO include those with diabetes, opioid-induced gut dysmotility and partial obstructive disease. In these patients, there is an interest in studying medications that can increase the number of phase III migrating motor complexes, such as 5-HT4 agonists (e.g. prucalopride) and motilin receptor agonists (e.g. erythromycin and azithromycin) to potentially decrease SIBO recurrence [26] . At this point, no further studies using pro-motility agents in SSc have been published.
TABLE 3
Methodological quality of included studies based on Newcastle-Ottawa Scale for Non-randomized studies Rifaximin administered 400 mg three times daily (total dose 1200 mg/day) eradicated SIBO in a small, non-randomized study [21] . The study was limited in that it used a diagnostic tool in the form of a lactulose breath test for SIBO detection in lieu of jejunal culture. As in the general SSc population, the vast majority of patients with SSc were women. Interestingly, one of the patients included in the cases had limited SSc. The severity of SSc in patients ranged from mild to moderate on the Eustar severity score, where 0 represents normal and 4 represents terminal. The majority of patients scored 12 on this scale, with only two patients scoring a 3 and none scoring a 4. This study involved the largest sample population with SSc and SIBO in this systematic analysis (n = 30). Lactulose breath testing was used to confirm that SIBO was eradicated in 22/30 (73%) of SSc patients. The study controlled for alimentation and ensured patients were not taking antibiotics, probiotics or anti-secretory drugs. However, patients were permitted to continue their PPIs.
Patients treated with PPIs have been shown to have increased duodenal bacterial overgrowth thought to be secondary to a reduction in gastric acid [27] . A recent meta-analysis confirmed a statistically significant association between increased risk of SIBO and PPI use ( odds ratio = 1.71, 95% CI: 1.20, 2.43) [28] . There was no statistically significant association for studies that used lactose as the substrate but there was for those that used glucose, highlighting possible differences in the substrates used. A North American Consensus Group did not recommend stopping PPIs before breath testing as PPIs do not alter breath testing and may cause intolerable reflux symptoms [13] .
In a recent meta-analysis by Shah et al. [29] on rifaximin effectiveness for all patients with SIBO (excluding patients with SSc), 1200 mg daily was considered a medium dose and effectiveness was correlated with medication dose. In total, the meta-analysis identified 67 subjects who received rifaximin compared with 49 who received placebo. Overall, the effectiveness ratio was 1.97 (95% CI: 0.93, 4.17) [29] . Notably, the confidence interval does cross zero, and this lack of statistical significance was attributed to the small sample size.
Eight patients with SIBO and SSc were treated with antibiotics in a non-randomized, un-controlled study conducted in the 1990s [20] . This represents the smallest cohort in this review. Patients were fasted and told to avoid high-fibre foods, but there was no mention of stopping any of their home medications. All eight patients responded to ciprofloxacin, including two patients initially trialled on trimethoprim with only partial effectiveness. In a small study of patients with Crohn's disease with SIBO, a 100% breath test normalization rate was seen in the 14 patients in the ciprofloxacin treatment arm [26] .
The two remaining studies both used a combination of antibiotics to treat SIBO in SSc. Marie et al.'s [7] trial of norfloxacin and metronidazole resulted in eradication of SIBO in 7/21 (31.8%) after 3 months and 11/21 (52.4%) after an additional 3 months of antibiotics. The study controlled for the confounding variables of antibiotics and probiotics, but all SSc patients were taking PPIs and the prokinetic medication domperidone at the time of the glucose breath test. It is important to note that in this study, both cases and controls received prokinetics such as domperidone and PPIs, so this should not confound the results of the study.
Fourteen patients in the Tauber et al. [10] study were treated with a successive antibiotic course recommended by EULAR, which included amoxicillin, ciprofloxacin and metronidazole. SIBO was eradicated (42.9%) in six of these patients, but two were lost to follow-up and two died, one of whom was positive for C. difficile. In the meta-analysis, which included patients with non-SScassociated SIBO, when any antibiotic was compared with placebo, the effectiveness ratio was 2.55 (95% CI: 1.29, 5.04), which was statistically significant, but only based on four studies [29] .
Although some trials commented on the percent of patients with diffuse or limited cutaneous SSc, the proportion of patients in each subset of SSc patients who tested positive for SIBO was not consistently or clearly reported. Tauber et al. [10] reported that among SSc patients with SIBO, the proportion of patients with diffuse subcutaneous SSc was the same as in those without SIBO (36 vs 39%, respectively) [10] . In the same study, SSc patients with SIBO were anti-topoisomerase antibody-positive at a frequency of 1/14 (7%) vs 9/23 (39%) of those with SSc but no SIBO [10] . Additionally, multiple studies commented that most SSc patients who were tested for SIBO continued their PPI, but no comment was made on the proportion of controls on PPIs. This is a potential confounder given that PPI use may by a risk factor for SIBO [30] .
A recent meta-analysis investigating probiotics for preventing or treating patients with SIBO reported that abdominal pain and hydrogen concentrations were reduced and SIBO eradicated (relative risk of SIBO eradication rate is 1.61, with a 95% CI: 1.19, 2.017), but it was not effectively prevented [18] . Our review did not reveal any studies that investigated the use of probiotics in SSc patients with SIBO.
Overall, the five studies reported in our systematic review reflect low quality data, as all received a score 46 on the Newcastle-Ottawa Scale and had high risk of bias as per the Cochrane Risk of Bias assessment tool. There were only 78 cases of SSc patients with SIBO reported. Methods used to measure the presence or absence of SIBO were variable among the studies. As such, the results should be interpreted with caution and the overall generalizability remains low.
Limitations
The systematic review itself was robust, however, the studies generally report low quality data with a relatively high risk of bias. Despite this search including all citations in MEDLINE, EMBASE and the Cochrane Library, no randomized controlled trials were identified. This is likely a result of the fact that SSc is a rare disease and thus randomized controlled trials are difficult to complete.
Practice implications
Given the small amount and generally low quality of evidence, this study cannot inform clinical practice about the most effective strategies for treating SIBO in patients with SSc. Given the potential for well known risks associated with antibiotics regimens such as the development of C. difficile, each patient's treatment course should be individualized. SSc GI guidelines are available through EULAR [9, 14, 15] . Current recommendations do recommend intermittent or rotating antibiotics to treat SIBO in patients with SSc, based on expert opinion [14] .
Research implications
With SSc being a rare disease, the potential for a largescale randomized controlled trial is limited. Thus, the best evidence for the use of treatment strategies in this population may come from longitudinal cohort studies, which could provide insight into potentially important covariates such as antibody expression, limited or diffuse cutaneous phenotype, comorbidities, smoking and PPI utilization. Additionally, cohort studies would allow for follow-up and outcomes focusing on morbidity and mortality.
In our systematic review, the type, doses and duration of treatments were heterogeneous between studies possibly because of the paucity of data to guide treatment options. Further research regarding SIBO therapy in patients with SSc is warranted for rifaximin and other antibiotics, prokinetics and other promotility agents, probiotics and other natural therapies. Although, octreotide and ciprofloxacin had higher eradication rates in our systematic review, these studies were smaller and there is more evidence for rifaximin treatment for SIBO for non-SSc populations. An ideal study would be a randomized controlled trial of rifaximin vs usual care in SSc patients using the latest Consensus Guidelines to diagnose SIBO based on breath testing with appropriate preparation. Outcome measures would be eradication of SIBO based on breath testing. This study would be difficult to power given the rarity of the disease. Perhaps as newer treatments target fibrosis [31] , one could also determine whether immunosuppressant or anti-fibrotic therapies reduce the incidence of gut dysmotility and ultimately prevent the onset of SIBO.
Conclusions
There is a paucity of evidence to determine whether prokinetics or probiotics are beneficial in the treatment of SIBO in patients with SSc. Based on low quality data, there is some evidence that antibiotics can be effective in eradicating SIBO in some patients with SSc.
